为庆祝这一事件,2024年5月9日,美国哥伦比亚大学欧文医学中心顾伟教授课题组(刘彦卿博士为第一作者)应邀在Cancer Cell杂志撰写了题为:Understanding the complexity of p53 in a new era of tumor suppression的长文综述。 该综述全方位地总结了p53的...
However, mutation of TP53 and the resultant inactivation of p53 allow evasion of tumour cell death and rapid tumour progression. The high frequency of TP53 mutation in tumours has prompted efforts to restore normal function of mutant p53 and thereby trigger tumour cell death and tumour elimination...
p53 is a tumour suppressor involved in controlling the balance between cell survival and death upon stresses, including chemotherapeutics9. p53 is frequently mutated in a variety of cancers, leading to loss of protein expression or expression of a mutated protein. Many mutant p53 proteins acquire ga...
MDM2抑制剂可与BCL-2抑制剂venetoclax联用。2017年发表在Cancer Cell的文章表明，这些试剂可以起到协同的...
Hu W, Feng Z. Gain-of-function mutant p53 in cancer progression and therapy. J Mol Cell Biol...
PDGFRb Mediates Mutant p53 Action in Human Cancer Cells To determine if the mutant p53-PDGFRb signaling axis acts in human cancer cells, we analyzed PDGFRb expression levels in a panel of human pancreatic cancer cell lines. As in our model, PDGFRb mRNA levels were significantly higher in cells...
In this study, more than three hundred colorectal cancer patients' samples were firstly analyzed, and the results showed that patients with mutant p53 had higher levels of AKT phosphorylation and PD-L1 expression, which were next verified both in cell lines in vitro and patients' samples in ...
Expression of the p53 gene was not detected at all by RT-PCR in two of the nine cell lines. In these two cell lines, Southern blot analysis showed gross rearrangements and deletions in both of the p53 alleles. Six of the nine cell lines were found to express only mutant p53 mRNA by ...
In early studies, expression of mutant p53 was demonstrated in breast cancer cell lines [6]. Loss of heterozygosity (LOH) in the p53 gene was shown to be a common event in primary breast carcinomas [7] and this is accompanied by mutation of the residual allele in some cases. In colon ...
6c). Similar results were also observed beyond CRC cell lines, PARP1 was activated by SC66 treatment in HepG2 cells with wild type p53, but not in DU145 cells, with mutant p53 (Fig. 6d). Next, in order to investigate whether p53 binds to PARP1 directly, co-immunoprecipitation assay ...